Technology | Contrast Media | July 15, 2019

FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients

Gadavist (gadobutrol) becomes first contrast agent FDA-approved for use in cardiac MR

FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance imaging (MRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). Gadavist (gadobutrol) is now the first and only contrast agent FDA-approved for use in cardiac MR, an important diagnostic tool for patients with CAD.

"Gadobutrol-enhanced cardiac MR demonstrated efficacy in a large global multicenter clinical trial," said Daniel S. Berman, M.D., FACC, chief of cardiac imaging and nuclear cardiology at the Cedars-Sinai Heart Institute and the S. Mark Taper Foundation Imaging Center. "The FDA approval is a landmark for making this validated, non-invasive method available to healthcare professionals to evaluate their patients for the most common form of heart disease in the world."

The approval was based on two multinational, non-randomized, blinded-read Phase 3 studies of almost 1,000 adults with suspected or known CAD based on signs and symptoms. Nearly 800 of those patients were evaluated for efficacy. First approved in 2011, cardiac MR is now the fourth FDA-approved indication for Gadavist.2

The Society for Cardiovascular Magnetic Resonance (SCMR) recognizes cardiac MR as a non-invasive tool that provides relevant and actionable information to healthcare professionals.3

"We now have an approved contrast agent for use in cardiac MR to assess perfusion and late gadolinium enhancement in less than one hour," said Scott Flamm, M.D., MBA, head of cardiovascular imaging, Cleveland Clinic. "A Gadavist-enhanced cardiac MR is a key diagnostic tool, providing additional important clinical information, which can help physicians manage their patients with known or suspected CAD."

A disease that affects approximately 16.5 million Americans, CAD develops when the major blood vessels that supply the heart with blood, oxygen and nutrients (coronary arteries) become damaged or diseased.1,5 Cholesterol-containing deposits (plaque) in the arteries and inflammation are usually the cause of CAD. When plaque builds up, it narrows the coronary arteries, decreasing blood flow to the heart. Eventually, the decreased blood flow may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms. A complete blockage can cause a heart attack.4

For more information: www.radiologysolutions.bayer.com

References

1. Cleveland Clinic. Coronary Artery Disease. https://my.clevelandclinic.org/health/diseases/16898-coronary-artery-disease. Updated May 14, 2019. Accessed May 23, 2019.

2. Gadavist (gadobutrol) Injection. Prescribing Information. Whippany, New Jersey, USA: Bayer Pharmaceuticals, Inc.

3. Society for Cardiovascular Magnetic Resonance: Why CMR. (n.d.). https://scmr.org/page/WhyCMR. Accessed May 23, 2019.     

4. Mayo Clinic. Coronary Artery Disease. https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613. Updated May 16, 2018. Accessed May 23, 2019.

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
USF Health Expands Digisonics System With Vascular Reporting
News | Cardiac PACS | October 17, 2019
University of South Florida (USF) Health in Tampa, Fla., has enhanced their use of the Digisonics Cardiovascular...
Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
At the annual meeting of the AHRA, Agfa Healthcare demonstrated a full-scale model of its DR 800, presenting the unit as a "game changer" for its multifunctionality.

At the annual meeting of the AHRA, Agfa Healthcare demonstrated a full-scale model of its DR 800, presenting the unit as a "game changer" for its multifunctionality.

Feature | AHRA | October 16, 2019 | By Greg Freiherr
Diversity was on display at the Association for Medical Imaging Mana...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
FDA Clears Modules of AI-Rad Companion Chest CT From Siemens Healthineers
Technology | Computed Tomography (CT) | September 26, 2019
The U.S. Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT, an intelligent...